Amna Ibrahim

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody

V. Ellen Maher, Laura L. Fernandes, Chana Weinstock et al. · Journal of Clinical Oncology · 2019 · 346 citations

Medicine, Oncology, Pharmacology +17

FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Laleh Amiri‐Kordestani, Gideon M. Blumenthal, Qiang Xu et al. · Clinical Cancer Research · 2014 · 345 citations

Medicine, Oncology, Pharmacology +17

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

Qin Ryan, Amna Ibrahim, Martin H. Cohen et al. · The Oncologist · 2008 · 308 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis

Jennifer Gao, Joyce Cheng, Erik Bloomquist et al. · The Lancet Oncology · 2019 · 297 citations

Medicine, Oncology, Pharmacology +17

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

Virginia E. Kwitkowski, Tatiana M. Prowell, Amna Ibrahim et al. · The Oncologist · 2010 · 249 citations · Full text

Medicine, Oncology, Pharmacotherapy +16